NOTE PURCHASE AGREEMENT
This Note
Purchase Agreement, dated as of February 11, 2009, (this “Agreement”) is entered into by
and among Organic To Go Food Corporation, a Delaware corporation (the “Company”), and X.Xxxxxx L.P.,
a limited partnership organized under the laws of the Bahamas (the “Investor”).
RECITALS
WHEREAS,
on the terms and subject to the conditions set forth herein, the Investor is
willing to purchase from the Company, and the Company is willing to sell to the
Investor, a secured promissory note in the principal amount of $5,000,000 in
substantially the form attached hereto as Exhibit A hereto (the
“Note”);
and
WHEREAS,
in connection with the sale of the Note the
Company shall enter into a security agreement granting a security interest in
all of the Company’s tangible and intangible assets, including, but not limited
to, the Company’s intellectual property rights, to the Investor, in substantially the form attached hereto as
Exhibit B (the
“Security
Agreement”).
AGREEMENT
NOW
THEREFORE, in consideration of the foregoing, and the representations,
warranties, and conditions set forth below, the parties hereto, intending to be
legally bound, hereby agree as follows:
1. The Note.
(a) Issuance of the
Note. At the Closing (as defined below), the Company agrees to
issue and sell to the Investor, and, subject to all of the terms and conditions
hereof, the Investor agrees to purchase the Note.
2. Procedure.
(a) Delivery. The
Closing (the “Closing”)
shall occur within seven (7) Business Days (as defined below) following the date
of this Agreement (the “Closing
Date”). At the Closing, the Company will deliver to the Investor the Note
against receipt by the Company of $5,000,000 (the “Purchase Price”), in United
States dollars and in immediately available funds, by wire transfer to an
account designated in writing by the Company. The Note will be registered in the
Investor’s name in the Company’s records. “Business Day” means any day
except Saturday, Sunday and any day which is a federal legal holiday in the
United States or in Switzerland, or a day on which banking institutions in the
State of New York are authorized or required by law or other governmental action
to close.
(b) Use of Proceeds. The proceeds
of the sale and issuance of the Note (the “Proceeds”) shall not be used
for the repayment of any loans incurred by the Company prior to
Closing. The Proceeds shall be used solely for (i) general working
capital and (ii) for funding new acquisitions and/or build up of new Greenfield
Cafes (as defined below) that are approved by the
Company’s Board of Directors. The Company shall continue to pay its other
obligations and liabilities in the ordinary course of its business as such
obligations and liabilities come due. For purposes of this Section, the term
“Greenfield Café” shall
mean any café that is newly established by the Company through direct
negotiations with a landlord or landlord's representative and excludes any
existing café that is acquired by the Company.
3. Representations
and Warranties of the Company. The Company hereby makes the
following representations and warranties to the Investor:
(a) Subsidiaries. The
Company has no direct or indirect Subsidiaries (as defined below) other than as
specified in all reports required to be filed by it under the Securities Act of
1933, as amended (the “Securities Act”), and the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), including
pursuant to Section 13(a) or 15(d) thereof, for the twelve months preceding the
date hereof (or such shorter period as the Company was required by law to file
such reports) (the foregoing materials being collectively referred to herein as
the “SEC
Reports”). Except as disclosed in Schedule 2(a), the
Company owns, directly or indirectly, all of the capital stock of each
Subsidiary free and clear of any and all Liens (as defined below), and all the
issued and outstanding shares of capital stock of each Subsidiary are validly
issued and are fully paid, non-assessable and free of preemptive and similar
rights. “Lien” means any
lien, charge, encumbrance, security interest, right of first refusal or other
restrictions of any kind. “Subsidiary” means any
“significant subsidiary” as defined in Rule 1-02(w) of the Regulation S-X
promulgated by the Securities and Exchange Commission (the “SEC”) under the Exchange
Act.
(b) Organization and
Qualification. The Company and each Subsidiary are duly
incorporated or otherwise organized, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or organization (as
applicable), with the requisite power and authority to own and use its
properties and assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in violation of
any of the provisions of its respective certificate or articles of
incorporation, bylaws or other organizational or charter
documents. The Company and each Subsidiary are duly qualified to
conduct its respective businesses and are in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the
business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may
be, could not, individually or in the aggregate, have or reasonably be expected
to result in a Material Adverse Effect. “Material Adverse Effect”
means any of (i) a material and adverse effect on the legality, validity or
enforceability of any Transaction Document (as defined below), (ii) a material
and adverse effect on the results of operations, assets, prospects, business or
condition (financial or otherwise) of the Company and the Subsidiaries, taken as
a whole, or (iii) an adverse impairment to the Company’s ability to perform on a
timely basis its obligations under any Transaction Document.
2
(c) Authorization;
Enforcement. The Company has the requisite corporate power and
authority to enter into and to consummate the transactions contemplated by each
of the Transaction Documents and otherwise to carry out its obligations
thereunder. The execution and delivery of each of the Transaction
Documents by the Company and the consummation by it of the transactions
contemplated thereby have been duly authorized by all necessary action on the
part of the Company and no further action is required by the Company in
connection therewith. Each Transaction Document has been (or upon
delivery will have been) duly executed by the Company and, when delivered in
accordance with the terms hereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in accordance with its
terms, except as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to,
or affecting generally the enforcement of, creditors’ rights and remedies or by
other equitable principles of general application.
(d) No
Conflicts. Except as set forth on Schedule 2(d), the
execution, delivery and performance of the Transaction Documents by the Company
and the consummation by the Company of the transactions contemplated thereby do
not and will not (i) conflict with or violate any provision of the Company’s or
any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational
or charter documents, or (ii) conflict with, or constitute a default (or an
event that with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument (evidencing a Company or Subsidiary
debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is
bound or affected, or (iii) result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or
Governmental Authority (as defined below) to which the Company or a
Subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a Subsidiary
is bound or affected; except in the case of each of clauses (ii) and (iii), such
as could not, individually or in the aggregate, have or reasonably be expected
to result in a Material Adverse Effect.
(e) Filings, Consents and
Approvals. Neither the Company nor any Subsidiary is required
to obtain any consent, waiver, authorization or order of, give any notice to, or
make any filing or registration with, any court or other federal, state, local
or other Governmental Authority in connection with the execution,
delivery and performance by the Company of the Transaction Documents, other than
(i) filings required by state securities laws, (ii) filings required in
accordance with Section 5(e), (iii) filings required pursuant to the Security
Agreement and (iv) those that have been made or obtained prior to the date of
this Agreement.
(f) Omitted
3
(g) Capitalization. The
number of shares and type of all authorized, issued and outstanding capital
stock of the Company, and all shares of the Company’s common stock, par value
$0.001 per share (the “Common
Stock”), reserved for issuance under the Company’s various option and
incentive plans, is specified in the SEC Reports. Except as specified
in the SEC Reports and as disclosed in Schedule 2(g), no
securities of the Company are entitled to preemptive or similar rights, and no
Person (as defined below) has any right of first refusal, preemptive right,
right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as specified in the
SEC Reports and except as set forth on
Schedule
2(g), there are no outstanding options, warrants, scrip rights to
subscribe to, calls or commitments of any character whatsoever relating to, or
securities, rights or obligations convertible into or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common
Stock, or contracts, commitments, understandings or arrangements by which the
Company or any Subsidiary is or may become bound to issue additional shares of
Common Stock, or securities or rights convertible or exchangeable into shares of
Common Stock. The issue and sale
of the Note will not, immediately or with the passage of time, obligate the
Company or any Subsidiary to issue shares of Common Stock or other securities to
any Person (other than the Investor) and will not result in a right of any
holder of Company or Subsidiary securities to adjust the exercise, conversion,
exchange or reset price under such securities. “Person” means an individual
or corporation, partnership, trust, incorporated or unincorporated association,
joint venture, limited liability company, joint stock company, government (or an
agency or subdivision thereof) or other entity of any kind.
(h) SEC Reports; Financial
Statements. Except as set forth on Schedule 2(h), the Company has filed all SEC Reports required to
be filed by it on a timely basis or has timely filed a valid extension of such
time of filing and has filed any such SEC Reports prior to the expiration of any
such extension. As of their respective dates, the SEC Reports
complied in all material respects with the requirements of the Securities Act
and the Exchange Act and the rules and regulations of the SEC promulgated
thereunder, and none of the SEC Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. Except
as set forth on Schedule 2(h), since
January 1, 2008, the Company has not received any material correspondence from
the SEC or any Trading Market (as defined below) concerning the SEC Reports. The
financial statements of the Company and any Subsidiary included in the SEC
Reports comply in all material respects with applicable accounting requirements
and the rules and regulations of the SEC with respect thereto as in effect at
the time of filing. Such financial statements have been prepared in
accordance with U.S. generally accepted accounting principles (“GAAP”) applied on a
consistent basis during the periods involved, except as may be otherwise
specified in such financial statements or the notes thereto, and fairly present
in all material respects the financial position of the Company and its
consolidated Subsidiaries as of and for the dates thereof and the results of
operations and cash flows for the periods then ended, subject, in the case of
unaudited statements, to normal, immaterial, year-end audit adjustments. “Trading Market” means
whichever of the New York Stock Exchange, the American Stock Exchange, the
NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market
or OTC Bulletin Board on which the Common Stock is listed or quoted for trading
on the date in question.
(i) Press
Releases. The press releases disseminated by the Company since
January 1, 2008, taken as a whole do not
contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made and when made,
not misleading.
4
(j) Material
Changes. Since the date of the latest audited financial
statements included within the SEC Reports, except as specifically disclosed in
the SEC Reports and except as disclosed on
Schedule
2(j), (i) there has been no event, occurrence or development that has had
or that could reasonably be expected to result in a Material Adverse Effect,
(ii) neither the Company nor any Subsidiary has entered into any material
contract, agreement or other transaction that is not in the ordinary course of
business, (iii) neither the Company nor any Subsidiary has incurred any
liabilities or obligations (contingent or otherwise) other than (A) trade
payables, accrued expenses and other liabilities incurred in the ordinary course
of business consistent with past practice, (B) liabilities not required to be
reflected in the Company’s financial statements pursuant to GAAP or required to
be disclosed in filings made with the SEC, and (C) liabilities not exceeding in
the aggregate $200,000; (iv) neither the Company nor any Subsidiary has altered
its method of accounting or the identity of its auditors, (v) neither the
Company nor any Subsidiary has declared or made any dividend or distribution of
cash or other property to its stockholders or purchased, redeemed or made any
agreements to purchase or redeem any shares of its capital stock, and (vi)
neither the Company nor any Subsidiary has issued any equity securities to any
officer, director or Affiliate (as defined below), except pursuant to existing
stock option plans. The Company does not have pending before the SEC any request
for confidential treatment of information. “Affiliate” means any Person
that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a Person, as such terms are used
in and construed under Rule 144.
(k) Litigation. Except
as set forth on Schedule 2(k), there
is no Action (as defined below) which (i) adversely affects or challenges the
legality, validity or enforceability of any of the Transaction Documents or (ii)
except as specifically disclosed in the SEC Reports, could, if there were an
unfavorable decision, individually or in the aggregate, have or reasonably be
expected to result in a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor any director or officer thereof (in his or her capacity
as such), is or has been the subject of any Action involving a claim of
violation of or liability under federal or state securities laws or a claim of
breach of fiduciary duty, except as specifically disclosed in the SEC
Reports. There has not been, and to the knowledge of the Company,
there is not pending any investigation by the SEC involving the Company, any
Subsidiary or any current or former director or officer of the Company (in his
or her capacity as such). The SEC has not issued any stop order or
other order suspending the effectiveness of any registration statement filed by
the Company or any Subsidiary under the Exchange Act or the Securities Act.
“Action” means any
action, suit, inquiry, notice of violation, proceeding (including any partial
proceeding such as a deposition) or investigation pending or threatened in
writing against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or
administrative agency, regulatory authority (federal, state, county, local or
foreign), stock market, stock exchange or trading facility.
5
(l) Labor
Relations. Except as set forth on Schedule 2(l), no
material labor dispute exists or, to the knowledge of the Company, is imminent
with respect to any of the employees of the Company or any
Subsidiary.
(m) Compliance. Except
as set forth on Schedule 2(m),
neither the Company nor any Subsidiary (i) is in default under or in violation
of (and no event has occurred that has not been waived that, with notice or
lapse of time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received notice of a
claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a
party or by which it or any of its properties is bound (whether or not such
default or violation has been waived), (ii) is in violation of any order of any
court, arbitrator or governmental body, or (iii) is or has been in violation of
any statute, rule or regulation of any Governmental Authority, including without
limitation all foreign, federal, state and local laws relating to taxes,
environmental protection, occupational health and safety, product quality and
safety and employment and labor matters, except in each case as could not,
individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect. The Company is in compliance with all effective
requirements of the Xxxxxxxx-Xxxxx Act of 2002, as amended, and the rules and
regulations thereunder, that are applicable to it, except where such
noncompliance could not have or reasonably be expected to result in a Material
Adverse Effect.
(n) Regulatory
Permits. The Company and the Subsidiaries possess all
certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their
respective businesses as described in the SEC Reports, except where the failure
to possess such permits could not, individually or in the aggregate, have or
reasonably be expected to result in a Material Adverse Effect, and neither the
Company nor any Subsidiary has received any notice of proceedings relating to
the revocation or modification of any such permits.
(o) Title to
Assets. Except as set forth on Schedule 2(o), the
Company and the Subsidiaries have good and marketable title in fee simple to all
real property owned by them that is material to their respective businesses and
good and marketable title in all personal property owned by them that is
material to their respective businesses, in each case free and clear of all
Liens, except for Liens as do not materially affect the value of such property
and do not materially interfere with the use made and proposed to be made of
such property by the Company and the Subsidiaries. Any real property and
facilities held under lease by the Company and the Subsidiaries are held by them
under valid, subsisting and enforceable leases of which the Company and the
Subsidiaries are in compliance, except as could not, individually or in the
aggregate, have or reasonably be expected to result in a Material Adverse
Effect.
(p) Patents and
Trademarks. The Company and the Subsidiaries have, or have
rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, copyrights, licenses and other similar
rights that are necessary or material for use in connection with their
respective businesses as described in the SEC Reports and which the failure to
so have could, individually or in the aggregate, have or reasonably be expected
to result in a Material Adverse Effect (collectively, the “Intellectual Property
Rights”). Except as set forth on Schedule 2(p),
neither the Company nor any Subsidiary has received a written notice that the
Intellectual Property Rights used by the Company or any Subsidiary violates or
infringes upon the rights of any Person. Except as set forth in the
SEC Reports, to the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person
of any of the Intellectual Property Rights.
6
(q) Insurance. The
Company and the Subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as are prudent
and customary in the businesses in which the Company and the Subsidiaries are
engaged. The Company is the named beneficiary of a key-man life
insurance policy with respect to its Chief Executive Officer for a coverage
amount of no less than $1,000,000. The Company has a directors and officers
liability insurance policy with respect to the Company’s Board of Directors for
a coverage amount of no less than $5,000,000. The Company has no reason to
believe that it will not be able to renew its and the Subsidiaries’ existing
insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business on
terms consistent with market for the Company’s and such Subsidiaries’ respective
lines of business.
(r) Transactions With Affiliates
and Employees. Except as set forth in or otherwise not
required to be disclosed in the SEC Reports and except with respect to the
transactions contemplated by the Transaction Documents, none of the officers or
directors of the Company and, to the knowledge of the Company, none of the
employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as
employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for
rental of real or personal property to or from, or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the
Company, any entity in which any officer, director, or any such employee has a
substantial interest or is an officer, director, trustee or
partner.
(s) Internal Accounting
Controls. The Company and the Subsidiaries maintain a system
of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management’s general or
specific authorizations, (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain
asset accountability, (iii) access to assets is permitted only in accordance
with management’s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any
differences. The Company has established disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
Company and designed such disclosure controls and procedures to ensure that
material information relating to the Company, including its Subsidiaries, is
made known to the certifying officers by others within those entities,
particularly during the period in which the Company’s Form 10-K or 10-Q, as the
case may be, is being prepared. The Company’s certifying officers
have evaluated the effectiveness of the Company’s controls and procedures in
accordance with Item 307 of Regulation S-K under the Exchange Act for the
Company’s most recently ended fiscal quarter or fiscal year-end (such date, the
“Evaluation
Date”). The Company presented in its most recently filed Form
10-K or Form 10-Q the conclusions of the certifying officers about the
effectiveness of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Since the Evaluation Date,
there have been no significant changes in the Company’s internal controls (as
such term is defined in Item 308T of Regulation S-K under the Exchange Act) or,
to the Company’s knowledge, in other factors that could significantly affect the
Company’s internal controls.
7
(t) Continuing
Operations. Based on the financial condition of the Company
and each Subsidiary as of the Closing Date (and assuming that the Closing shall
have occurred), the Company and each Subsidiary shall have sufficient capital to
carry on its business through the Maturity Date (as defined in the Note) as now
conducted and as proposed to be conducted including its capital needs taking
into account the particular capital requirements of the business conducted by
the Company and each Subsidiary, and projected capital requirements and capital
availability thereof.
(u) Certain
Fees. Except as described in Schedule 2(u), no
brokerage or finder’s fees or commissions are or will be payable by the Company
or any Subsidiary to any broker, financial advisor or consultant, finder,
placement agent, investment banker, bank or other Person with respect to the
transactions contemplated by this Agreement. The Investor shall have
no obligation with respect to any fees or with respect to any claims (other than
such fees or commissions owed by the Investor pursuant to written agreements
executed by the Investor which fees or commissions shall be the sole
responsibility of the Investor) made by or on behalf of other Person for fees of
a type contemplated in this Section 3(u) that may be due in connection with the
transactions contemplated by this Agreement.
(v) Certain Registration
Matters. Assuming the accuracy of the Investor’s
representations and warranties set forth in Section 4, no registration under the
Securities Act is required for the offer and sale of the Note by the Company to
the Investor under the Transaction Documents. The Company is eligible
to register its Common Stock for resale by the Investor under Form S-1
promulgated under the Securities Act. Except as specified in the SEC
Reports and except as set forth on Schedule 2(v),
neither the Company nor any Subsidiary has granted or agreed to grant to any
Person any rights (including “piggy-back” registration rights) to have any
securities of the Company registered with the SEC or any other Governmental
Authority that have not been satisfied.
(w) Listing and Maintenance
Requirements. Except as specified in the SEC Reports and
except as set forth on Schedule 2(h), the
Company has not, since January 1, 2008, received notice from any Trading Market
to the effect that the Company is not in compliance with the listing, quoting or
maintenance requirements thereof. The Company is, and has no reason
to believe that it will not in the foreseeable future continue to be, in
compliance with the listing, quoting or maintenance requirements for continued
listing or quoting of the Common Stock on the Trading Market on which the Common
Stock is currently listed or quoted. The issuance and sale of the
Note under the Transaction Documents does not contravene the rules and
regulations of the Trading Market on which the Common Stock is currently listed
or quoted, and no approval of the stockholders of the Company thereunder is
required for the Company to issue and deliver to the Investor the Note
contemplated by Transaction Documents.
8
(x) Investment
Company. The Company and each Subsidiary is not, and is not an
Affiliate of, and immediately following the Closing will not have become, an
“investment company” within the meaning of the Investment Company Act of 1940,
as amended.
(y) Application of Takeover
Protections. The Company has taken all necessary action, if
any, in order to render inapplicable any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s certificate of
incorporation (or similar charter documents) or the laws of its state of
incorporation that is or could become applicable to the Investor as a result of
the Investor and the Company fulfilling their obligations or exercising their
rights under the Transaction Documents, including without limitation the
Company’s issuance of the Note and the Investor’s ownership of the
Note.
(z) No Additional
Agreements. The Company does not have any agreement or
understanding with the Investor with respect to the transactions contemplated by
the Transaction Documents other than as specified in the Transaction
Documents.
(aa) Consultation with
Auditors. The Company and each Subsidiary has consulted its
independent auditors concerning the accounting treatment of the transactions
contemplated by the Transaction Documents, and in connection therewith has
furnished such auditors complete copies of the Transaction
Documents.
(bb) Foreign Corrupt Practices
Act. Neither the Company nor any Subsidiary, nor to the
knowledge of the Company, any agent or other person acting on behalf of any of
the Company or any Subsidiary, has, directly or indirectly, (i) used any funds,
or will use any proceeds from the sale of the Note, for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic
political activity, (ii) made any unlawful payment to foreign or domestic
government officials or employees or to any foreign or domestic political
parties or campaigns from corporate funds, (iii) failed to disclose fully any
contribution made by the Company or any Subsidiary (or made by any Person acting
on their behalf of which the Company is aware) which is in violation of law, or
(iv) has violated in any material respect any provision of the Foreign Corrupt
Practices Act of 1977, as amended, and the rules and regulations
thereunder.
(cc) PFIC. Neither
the Company nor any Subsidiary is or intends to become a “passive foreign
investment company” within the meaning of Section 1297 of the U.S. Internal
Revenue Code of 1986, as amended.
(dd) OFAC. Neither the
Company nor any Subsidiary nor, to the knowledge of the Company, any director,
officer, agent, employee, Affiliate or Person acting on behalf of the Company or
any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will
not directly or indirectly use the proceeds of the sale of the Note, or lend,
contribute or otherwise make available such proceeds to any Subsidiary, joint
venture partner or other Person or entity, towards any sales or operations in
Cuba, Iran, Syria, Sudan, Myanmar or any other country sanctioned by OFAC or for
the purpose of financing the activities of any Person currently subject to any
U.S. sanctions administered by OFAC.
9
(ee) Money Laundering
Laws. The operations of each of the Company and any Subsidiary are and
have been conducted at all times in compliance with the money laundering
statutes of applicable jurisdictions, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or
enforced by any applicable governmental agency (collectively, the “Money Laundering Laws”) and no
action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company and/or any Subsidiary
with respect to the Money Laundering Laws is pending or, to the best knowledge
of the Company, threatened.
(ff) Dependence on Major
Customers. No single customer of the Company or any of its
Subsidiaries accounted for more than 10% of the Company’s or any of its
Subsidiaries’ total sales during the calendar year of 2007.
(gg) Disclosure. All
disclosure provided to the Investor regarding the Company (including each
Subsidiary), its and any Subsidiary’s business and the transactions contemplated
hereby, furnished by or on behalf of the Company (including the Company’s
representations and warranties set forth in this Agreement) are true and correct
and do not contain any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements made therein, in light
of the circumstances under which they were made, not misleading.
4. Representations
and Warranties of the Investor. The Investor hereby
represents and warrants to the Company as follows:
(a) This
Agreement is made by the Company with the Investor who is a Non-U.S. Person in
reliance upon such Non-U.S. Person’s representations, warranties and covenants
made in this Section 4.
(b) Such
Non-U.S. Person has been advised and acknowledges that (i) the Note has not
been, and when issued, will not be registered under the Securities Act, the
securities laws of any state of the United States or the securities laws of any
other country; (ii) in issuing and selling the Note to such Non-U.S. Person
pursuant hereto, the Company is relying upon the “safe harbor” provided by
Regulation S and/or on Section 4(2) under the Securities Act; (iii) it is a
condition to the availability of the Regulation S “safe harbor” that the Note
not be offered or sold in the United States or to a U.S. Person until the
expiration of a period of six (6) months following the Closing Date; (iv)
notwithstanding the foregoing, prior to the expiration of six (6) months after
the Closing (the “Restricted
Period”), the Note may be offered and sold by the holder thereof only if
such offer and sale is made in compliance with the terms of this Agreement and
either: (A) if the offer or sale is within the United States or to or
for the account of a U.S. Person, the Note is offered and sold pursuant to an
effective registration statement or pursuant to Rule 144 under the Securities
Act or pursuant to an exemption from the registration requirements of the
Securities Act; or (B) the offer and sale is outside the United States and to
other than a U.S. Person.
10
(c) As used
in this Agreement, the term “United States” means and
includes the United States of America, its territories and possessions, any
State of the United States, and the District of Columbia, the term “U.S. Person” means: (i) a
natural person resident in the United States; (ii) any partnership or
corporation organized or incorporated under the laws of the United States; (iii)
any estate of which any executor or administrator is a U.S. person; (iv) any
trust of which any trustee is a U.S. person; (v) any agency or branch of a
foreign entity located in the United States; (vi) any nondiscretionary account
or similar account (other than an estate or trust) held by a dealer or other
fiduciary for the benefit or account of a U.S. person; (vii) any discretionary
account or similar account (other than an estate or trust) held by a dealer or
other fiduciary organized, incorporated and (if an individual) resident in the
United States; or (viii) a corporation or partnership organized under the laws
of any foreign jurisdiction and formed by a U.S. person principally for the
purpose of investing in securities not registered under the Securities Act,
unless it is organized or incorporated, and owned, by accredited investors (as
defined in Rule 501(a) under the Securities Act) who are not natural persons,
estates or trusts, and the term “Non-U.S. Person” means any
person who is not a U.S. Person or is deemed not to be a U.S. Person under Rule
902(k)(2) of the Securities Act.
(d) Such
Non-U.S. Person agrees that with respect to the Note until the expiration of the
Restricted Period: (i) such Non-U.S. Person, its agents or its representatives
have not and will not solicit offers to buy, offer for sale or sell the Note, or
any beneficial interest therein in the United States or to or for the account of
a U.S. Person during the Restricted Period; (ii) notwithstanding the foregoing,
prior to the expiration of the Restricted Period, the Note may be offered and
sold by the holder thereof only if such offer and sale is made in compliance
with the terms of this Agreement and either: (A) if the offer or sale
is within the United States or to or for the account of a U.S. Person, the Note
is offered and sold pursuant to an effective registration statement or pursuant
to Rule 144 under the Securities Act or pursuant to an exemption from the
registration requirements of the Securities Act; or (B) the offer and sale is
outside the United States and to other than a U.S. Person; and (iii) such
Non-U.S. Person shall not engage in hedging transactions with regard to the Note
unless in compliance with the Securities Act. The foregoing restrictions are
binding upon subsequent transferees of the Note, except for transferees pursuant
to an effective registration statement. Such Non-U.S. Person agrees
that after the Restricted Period, the Note may be offered or sold within the
United States or to or for the account of a U.S. Person only pursuant to
applicable securities laws.
(e) Such
Non-U.S. Person has not engaged, nor is it aware that any party has engaged, and
such Non-U.S. Person will not engage or cause any third party to engage, in any
directed selling efforts (as such term is defined in Regulation S) in the United
States with respect to the Note.
(f) Such
Non-U.S. Person: (i) is domiciled and has its principal place of
business outside the United States; (ii) certifies it is not a U.S. Person and
is not acquiring the Note for the account or benefit of any U.S. Person; and
(iii) at the time of the Closing Date, the Non-U.S. Person or persons acting on
Non-U.S. Person’s behalf in connection therewith will be located outside the
United States.
11
(g) At the
time of offering to such Non-U.S. Person and communication of such Non-U.S.
Person’s order to purchase the Note and at the time of such Non-U.S. Person’s
execution of this Agreement, the Non-U.S. Person or persons acting on Non-U.S.
Person’s behalf in connection therewith were located outside the United
States.
(h) Such
Non-U.S. Person is not a “distributor” (as defined in Regulation S) or a
“dealer” (as defined in the Securities Act).
(i) Such
Non-U.S. Person acknowledges that the Company shall make a notation in its stock
books regarding the restrictions on transfer set forth in this Section 4
and shall transfer the Note on the books of the Company only to the extent
consistent therewith. In particular, such Non-U.S. Person acknowledges that the
Company shall refuse to register any transfer of the Note not made in accordance
with the provisions of Regulation S, pursuant to registration under the
Securities Act or pursuant to an available exemption from
registration.
(j) The
Investor understands and agrees that the Note being issued hereunder shall bear
the legend set forth on the form attached hereto as Exhibit A,
until (i) the Note is registered under the Securities Act pursuant to a
registration statement that has been declared effective or (ii) in the opinion
of counsel reasonably acceptable to the Company, the Note may be sold without
registration under the Securities Act as well as any applicable “Blue Sky” or
state securities laws.
(k) The
Investor hereby represents that the Investor is satisfied as to the full
observance of the laws of such Investor’s jurisdiction in connection with any
invitation to subscribe for the Note, including (i) the legal requirements
within such Investor’s jurisdiction for the purchase of the Note, (ii) any
foreign exchange restrictions applicable to such purchase, (iii) any
governmental or other consents that may need to be obtained and (iv) the income
tax and other tax consequences, if any, that may be relevant to the purchase,
holding, redemption, sale or transfer of the Note. Such Investor’s
subscription and payment for, and such Investor’s continued beneficial ownership
of, the Note, will not violate any applicable securities or other laws of such
Investor’s jurisdiction.
(l) The
Investor has full power and authority to enter into this Agreement, the
execution and delivery of which has been duly authorized, if applicable, and
this Agreement constitutes a valid and legally binding obligation of the
Investor enforceable against the Investor in accordance with its terms, except
as such enforceability may be limited by general principles of equity or to
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and
other similar laws relating to, or affecting generally, the enforcement of
applicable creditors’ rights and remedies.
(m) The information in the “Investor
Questionnaire,” attached hereto as Exhibit C, completed and
executed by the Investor (the “Investor Questionnaire”) is
accurate and true in all material respects.
12
(n) The
Investor is not relying on the Company or its Affiliates with respect to
economic considerations involved in this investment.
(o) The
Investor understands and agrees that the Investor must bear the economic risk of
the Investor’s purchase because, among other reasons, the Note has not been
registered under the Securities Act or under the securities laws of any state
and, therefore, cannot be resold, assigned or otherwise disposed of unless they
are subsequently registered under the Securities Act and under the applicable
securities laws of such states, or an exemption from such registration is
available.
(p) No
representations or warranties have been made to the Investor by the Company or
any of its officers, employees, agents, Affiliates or subsidiaries, other than
any representations of the Company contained herein, and in subscribing for the
Note the Investor is not relying upon any representations other than any
contained herein; provided that nothing contained herein shall modify, amend or
affect the Investor’s right to rely on the Company’s representations and
warranties contained herein.
(q) The
Investor understands and acknowledges that the Investor’s purchase of the Note
is a speculative investment that involves a high degree of risk and the
potential loss of the Investor’s entire investment.
(r) Neither
the SEC nor any state securities commission has approved the Note, or passed
upon or endorsed the merits of this offering or confirmed the accuracy or
determined the adequacy of any information provided to the Investor by the
Company.
(s) The
Investor and the Investor’s advisors, if any, have had a reasonable opportunity
to ask questions of and receive answers from a person or persons acting on
behalf of the Company concerning the offering and the business, financial
condition, results of operations and prospects of the Company, and all such
questions have been answered to the reasonable satisfaction of the Investor and
the Investor’s advisors, if any.
(t) The
Investor is unaware of, is in no way relying on, and did not become aware of the
offering through or as a result of, any article, notice, advertisement or other
communication published in any newspaper, magazine or similar media or broadcast
over television, radio or over the Internet, in connection with the offering and
sale of the Note and is not subscribing for the Note and did not become aware of
the offering of the Note through or as a result of any seminar or meeting to
which the Investor was invited by, or any solicitation of a subscription by, a
person not previously known to the Investor in connection with investments in
securities generally.
(u) The
Investor has not engaged any placement agent, financial advisor or broker, which
would give rise to any claim by any person for brokerage commissions, finders’
fees or the like relating to this Agreement or the transactions contemplated
hereby and, in turn, to be paid to other selected dealers.
(v) The
foregoing representations, warranties and agreements shall survive the
Closing.
13
5. Other
Agreements of the Parties.
(a)
The Note
may only be disposed of in compliance with state and federal securities
laws. In connection with any transfer of the Note other than pursuant
to an effective registration statement, to the Company, to an Affiliate of the
Investor or in connection with a pledge as contemplated in Section 5(b), the
Company may require the transferor thereof to provide to the Company an opinion
of counsel selected by the transferor, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred Note under the
Securities Act.
(b) The
Company acknowledges and agrees that the Investor may from time to time pledge,
and/or grant a security interest in some or all of the Note pursuant to a bona
fide margin agreement in connection with a bona fide margin account and, if
required under the terms of such agreement or account, such Investor may
transfer the pledged or secured Note to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval
or consent of the Company and no legal opinion of legal counsel to the pledgee,
secured party or pledgor shall be required in connection with the pledge, but
such legal opinion may be required in connection with a subsequent transfer
following default by the Investor transferee of the pledge. No notice
shall be required of such pledge. At the appropriate Investor’s
expense, the Company will execute and deliver such reasonable documentation as a
pledgee or secured party of the Note may reasonably request in connection with a
pledge or transfer of the Note.
(c) As long
as the Investor owns the Note, the Company covenants to timely file (or obtain
extensions in respect thereof and file within the applicable grace period) all
reports required to be filed by the Company after the date hereof pursuant to
the Exchange Act.
(d) The
Company shall not, and shall use its best efforts to ensure that no Affiliate of
the Company shall, sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any security (as defined in Section 2 of the Securities
Act) that would be integrated with the offer or sale of the Note in a manner
that would require the registration under the Securities Act of the sale of the
Note to the Investor, or that would be integrated with the offer or sale of the
Note for purposes of the rules and regulations of any Trading Market in a manner
that would require stockholder approval of the sale of the Note to the
Investor.
(e) By 9:00
a.m. (New York time) four (4) Trading Days following the execution of this
Agreement, and by 9:00 a.m. (New York time) four (4) Trading Days following the
Closing Date, the Company shall issue press releases disclosing the transactions
contemplated hereby and the Closing. Within four (4) Trading Days
following the execution of this Agreement, the Company will file a current
report on Form 8-K disclosing the material terms of the Transaction Documents
(and attach as exhibits thereto the Transaction Documents), and within four (4)
Trading Days following the Closing Date the Company will file an additional
current report on Form 8-K to disclose the Closing. In addition, the
Company will make such other filings and notices in the manner and time required
by the SEC and the Trading Market on which the Common Stock is quoted or listed
in connection with the Transaction Documents. “Trading Day” means (i) a day
on which the Common Stock is traded on a Trading Market (other than the OTC
Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market
(other than the OTC Bulletin Board), a day on which the Common Stock is traded
in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii)
if the Common Stock is not quoted on any Trading Market, a day on which the
Common Stock is quoted in the over-the-counter market as reported by the Pink
Sheets LLC (or any similar organization or agency succeeding to its functions of
reporting prices); provided, that in the event that the Common Stock is not
listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day
shall mean a Business Day.
14
(f) In
addition to the indemnity provided in any other Transaction Document, the
Company will indemnify and hold the Investor and its directors, officers,
shareholders, partners, employees and agents (each, an “Investor Party”) harmless
from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys’ fees and costs of
investigation that any such Investor Party may suffer or incur as a result of or
relating to any misrepresentation, breach or inaccuracy of any representation,
warranty, covenant or agreement made by the Company in any Transaction
Document. In addition to the indemnity contained herein, the Company
will reimburse each Investor Party for its reasonable legal and other expenses
(including the cost of any investigation, preparation and travel in connection
therewith) incurred in connection therewith, as such expenses are
incurred.
The
Company covenants and agrees that neither it nor any other Person acting on its
behalf will provide the Investor or its agents or counsel with any information
that the Company believes constitutes material non-public information, unless
prior thereto such Investor shall have executed a written agreement regarding
the confidentiality and use of such information. The Company
understands and confirms that the Investor shall be relying on the foregoing
representations in effecting transactions in securities of the
Company.
(g) Prior to
the Closing, Company will not, without the Investor's prior written consent: (i)
change the nature of its business; (ii) issue any equity, equity securities
(other than stock options issued pursuant to the Company’s Stock Plan (as
defined below) in the ordinary course of business) or debt in any form exceeding
in value $250,000; (iii) divest, acquire, change the structure of its assets or
otherwise decrease the value of its assets; or (iv) enter into any
collaboration, partnership, distribution or other agreement binding Company to
any future payments, services or other contractual obligations exceeding in
value $250,000. The term “Stock
Plan” shall mean any stock option or stock incentive plan reserved for
Company officers, directors, employees or consultants and approved by the Board
of Directors of the Company with the affirmative vote of the Investor
Director(s) (as defined below).
(h) As long
as the Note remains outstanding, and to the maximum extent permitted by law, the
Company waives any of its rights for automatic stay pursuant to Section 362 to
Title 11 of the United States Code (commonly referred to as the Bankruptcy Code)
that may be triggered under any bankruptcy proceedings, in order to permit the
Investor to enforce its rights under the Note and the Security
Agreement.
15
(i) The
Company will keep the existence and content of its negotiations with the
Investor, including the terms of the Transaction Documents, confidential and
will not disclose to any third party any information relating to the
transactions hereunder, except to its employees, shareholders, Affiliates,
counsel or consultants, who will each be bound by confidentiality agreements and
who will have a ‘need to know’, and except as required by law. Except
as required by applicable law, the Company will make no public statement, press
release, or other announcement with respect to the transactions hereunder,
without the Investor’s prior written approval. The Investor will maintain all
confidential information it obtains from the Company in accordance with the
provisions of that certain Confidentiality Agreement, dated as of December 26,
2007, by and between the Investor and the Company. Notwithstanding the
foregoing, any activities undertaken by the Investor on behalf of the Company,
such as discussions with potential investors or strategic partners, will not be
deemed to be a breach of the Investor’s confidentiality
obligations.
(j) The
Investor and the Company agree not to engage in any activities designed to
manipulate the trading price of the Common Stock.
(k) The
Company will ensure that any and all transfers of personal information to the
Investor concerning employees of the Company or any other individuals will be in
compliance with all applicable data protection laws and
regulations.
(l) Promptly
following the Closing, the Stock Plan shall be amended such that all securities
issued pursuant to the Stock Plan will be subject to vesting over a period of
four (4) years and twenty five percent (25%) of such securities will vest at the
end of the each year following such issuance. A sufficient number of
shares of the Company's Common Stock, as determined by the Board of Directors,
will be reserved for future allocation of securities for compensation of
management pursuant to the Stock Plan and in accordance with the current
management incentive structure of the Company. If the employment of any
Key Employee (as defined below) terminates before the end of its vesting period,
all of such Key Employee’s non-vested securities will expire in accordance with
the terms of employment of such Key Employee. The term “Key Employee” shall mean each
of Xxxxx Xxxxx, Xxxxxxx Xxxx and Xxxxxxx Xxxxxxx.
(m) If
prior to the fourth (4th) anniversary of the Closing, the employment of a Key
Employee is terminated for “Cause” (as defined in such Key Employee’s employment
agreement) or a Key Employee terminates his or her employment with the Company
without “Good Reason” (as defined in such Key Employee’s employment agreement),
the Company shall have the right to repurchase any outstanding vested or
unvested options or restricted stock of the Company owned by such Key Employee
on the date of such termination at a price equal to the lower of the prevailing
market price and the original issue price of such options or restricted
stock. The Company shall implement the foregoing repurchase
arrangements within 30 days following the Closing. If prior to the
fourth (4th) anniversary of the Closing, the employment of a Key Employee is
terminated without Cause or a Key Employee terminates his or her employment with
the Company for Good Reason, such Key Employee shall retain any
vested securities of the Company owned by such Key Employee on the date of such
termination.
16
(n) Save for Excluded
Issuances (as defined below), the Company will not issue any securities without
first offering such securities to the Investor in proportion to the Investor’s
percentage ownership of the Company’s issued and outstanding share capital on an
“as converted” basis at the time of the proposed new issue. The term “Excluded Issuance” shall
include any (A) securities issued or issuable to lenders, licensors and leasing
institutions pursuant to any financing, lending or leasing transaction approved
by the Board of Directors of the Company, including the affirmative vote of the
majority of the Investor Director, (B) securities issued by reason of a
dividend, including any bonus shares, stock split, split-up, recapitalization,
reclassification, (C) securities issued to employees or directors of, or
consultants or advisors to, the Company or any subsidiary pursuant to the
Company Stock Plan, and any shares of Common Stock issued upon the exercise of
such securities or upon the exercise of any warrants or options of the Company
that were outstanding as of the Closing, (D) securities issued in a merger,
acquisition or similar transaction approved by the Board of Directors of the
Company, including the affirmative vote of the majority of the Investor
Directors, or (E) securities issued upon conversion of any preferred stock of
the Company.
(o) The Board
of Directors shall meet at least once every quarter upon a prior
written request of at least ten (10) days of any of the Investor
Directors. Such meeting shall occur in person if possible. The
Investor Directors shall have the right to determine the location of at least
two (2) in-person Board of Directors’ meetings per year, which the members of
the Board of Directors shall physically attend. The Company shall
reimburse the members of the Board of Directors for all out-of-pocket expenses
incurred by the members in connection with attendance at the meetings of the
Board of Directors.
(p) Upon the
written request of the Investor, the Company will permit one representative
designated by the Investor in writing (the “Observer”) to attend all
meetings of the Board and all committees thereof (whether in person, telephonic
or other) in a non-voting, observer capacity, and shall provide to the Observer,
concurrently with the members of the Board, and in the same manner, notice of
such meeting and a copy of all materials provided to such members, and shall pay
any “out-of-pocket” expenses of the Observer to attend Board
meetings.
(q) At all
meetings of the Board of Directors, a majority of the authorized number of
directors, such majority to include at least three (3) of the Investor
Directors, shall constitute a quorum for the transaction of
business. If a quorum is not present at any meeting of the Board of
Directors, then the directors present thereat may adjourn the meeting to such
time, date and place as they may determine, provided that not less than seven
(7) Business Days’ written notice shall have been provided to each of the
directors of such meeting. At such adjourned meeting, a majority of
the authorized number of directors, such majority to include at least one (1) of
the Investor Directors shall constitute a quorum.
(r) Promptly
following Closing, the Board of Directors shall form an audit committee, which
shall include a majority of the Investor Directors and shall not include the
Chief Executive Officer of the Company. Such audit committee shall
review the actual and planned financials of the Company and communicate with the
Company’s auditors on a regular basis.
17
(s) The Board
of Directors shall have the right to appoint, in the name of the Company,
advisors, counsel, attorneys, consultants or other third parties to provide
strategic advice, scientific assessments, legal advice, general business
development advice or other specialist advice which, in the opinion of the
majority of the Investor Directors, would facilitate the fulfillment of the
directors’ roles as members of the Board of Directors. The Company
shall pay the reasonable fees of such board advisors.
(t) Subject
to the terms and conditions set forth in this Agreement, the Company shall use
its best efforts to take or cause to be taken all actions, and do or cause to be
done all things, reasonably necessary, proper or advisable on its part under
this Agreement to consummate and make effective the transactions contemplated
hereunder as soon as practicable, including the obtaining of all necessary
actions or nonactions, consents and approvals from all Persons necessary in
connection with the consummation of the transactions contemplated hereunder and
the taking of all reasonable steps as may be necessary to obtain an approval
from, or to avoid an action or proceeding by, any Person necessary in connection
with the consummation of the transactions contemplated hereunder.
(u) Promptly
following the Closing, the Company shall use its best efforts to obtain all
necessary consents and approvals from such Persons as are required in connection
with the consummation of the transactions contemplated under this Agreement and
the other Transaction Documents.
6. Conditions to
Closing of the Investor. The Investor’s obligations at the Closing are
subject to the fulfillment, on or prior to the Closing Date, of all of the
following conditions, any of which may be waived in whole or in part by the
Investor:
(a) Representations and
Warranties. The representations and warranties made by the Company in
Section 3 shall have been true and correct when made, and shall be true and
correct on the Closing Date.
(b) Performance. The
Company shall have performed, satisfied and complied in all material respects
with all covenants, agreements and conditions required by the Transaction
Documents to be performed, satisfied or complied with by it at or prior to the
Closing Date;
(c) No Injunction. No
statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by any court or Governmental
Authority of competent jurisdiction that prohibits the consummation of any of
the transactions contemplated by the Transaction Documents;
(d) Transaction
Documents. The Company shall have duly executed and delivered
to the Investor the following documents (together, the “Transaction
Documents”):
(i) this
Agreement;
(ii) the Note
issued in accordance with Section 2;
18
(iii) the
Security Agreement, as well as all ancillary documents required in order to
perfect the registration of the lien contemplated by the Security
Agreement;
(iv) the
Amendment to the Notes applicable to the June Notes (as defined
below);
(v) the
amendment to the December Note (as defined below);
(vi) the
Amendment to the Conditional Warrant (as defined below); and
(vii) the
Amended and Restated Registration Rights Agreement attached hereto as Exhibit G (the “Registration Rights
Agreement”).
(e) Officer’s Certificate. The
Company shall have delivered to the Investor a certificate of the Company, dated
as of the Closing Date, signed by the Chief Executive Officer of the Company,
confirming that (1) the amount of any loans or other forms of indebtedness
between the Company and any director, officer, key employee and/or consultant;
(2) that the Company’s projected payments on liabilities before Closing do not
exceed the projections provided in the Business Plan (as defined below); (3)
since the date of execution of this Agreement, no event or series of events
shall have occurred that reasonably could have or result in a Material Adverse
Effect and (4) the Company shall use its best efforts to appoint and hire a
qualified SVP of Operations satisfactory to the Investor, within reasonable time
following Closing;
(f) Legal Opinion. The Company
shall have delivered to the Investor a legal opinion of Loeb & Loeb LLP, in
agreed form, addressed to the Investor and a legal opinion of Xxxx XxXxxxxxx Xxxxxxxxx Xxxxxxxx & Xxxx
Professional Law Corporation, in agreed form, addressed to the
Investor;
(g) Good Standing
Certificate. The Company shall have delivered to the Investor
good standing certificates from (a) the State of Delaware and (b) the State of
Washington, dated as of no more than three (3) Business Days prior to the
Closing Date, certifying that the Company is in good standing and qualified to
do business in these jurisdictions;
(h) Secretary’s
Certificate. At
the Closing, the Company shall have delivered to the Investor a certificate duly
executed by the Secretary of the Company, having attached thereto and certified
resolutions approved by the Board of Directors of the Company authorizing the
transactions contemplated hereunder;
(i) Waivers. The
Company shall have delivered to the Investor validly executed waivers of
preemptive rights or any other rights that the stockholders of the Company may
have in connection with this Agreement and the transaction contemplated
hereunder, in a form reasonably suitable to the Investor; and
(j) No Suspensions of Trading in Common
Stock; Listing. Trading in the Common Stock shall not have
been suspended by the SEC or any Trading Market (except for any suspensions of
trading of not more than one Trading Day solely to permit dissemination of
material information regarding the Company) at any time since the date of
execution of this Agreement, and the Common Stock shall have been at all times
since such date listed or quoted for trading on a Trading Market.
19
(k) Confirmation of fulfillment of all
Closing Conditions. Upon Closing the law firm representing the
Investor (with respect to item (i) below) and the law firm representing the
Company (with respect to item (ii) below) shall provide the Investor with a
written statement confirming that (i) all Transaction Documents, other ancillary
documents and closing deliverables listed in this Section 5 have been drawn up
or amended, and (ii) all filings/notifications in connection with the
transactions contemplated under the Transaction Documents to the relevant
Governmental Authorities (including but not limited to the SEC) have been made.
The Company shall be responsible for future filings following the Closing in
accordance with the terms of this Agreement and the other Transaction
Documents;
(l) Due Diligence. The Investor
shall have completed customary due diligence and shall have received favorable
due diligence reports, including intellectual property, business, financial,
scientific and legal, in form, substance and outcome satisfactory to the
Investor;
(m) Business Plan. Prior to
Closing, the Investor shall have received the Company’s updated business plan,
which includes monthly projected income statements and cash flows for 2009 and
2010 (the “Business
Plan”);
(n) Employment Agreements. The
Company shall have entered into employment agreements, in form and substance
satisfactory to the Investor, with each of its Key Employees;
(o) Antitrust
Approval. (i) All required authorizations, consents, orders,
declarations or approvals of, or filings with, any applicable antitrust
authority in connection with this Agreement and the transactions contemplated
hereunder have been obtained by the Company or the Investor shall have received
an opinion from Howrey LLP or another law firm specializing in antitrust laws
stating that under applicable antitrust laws, no notices, reports or other
filings are required to be made by the Investor or the Company with, nor are any
consents, registrations, approvals, permits or authorizations required to be
obtained by the Investor or the Company from, any antitrust authority in
connection with the execution and delivery of this Agreement by the Investor and
the Company and the consummation of the transactions contemplated hereunder; and
(ii) any waiting period under the Xxxx-Xxxxx-Xxxxxx Antitrust improvements Act
of 1976 shall have elapsed;
(p) Filings; Consents;
Notification. All necessary actions or nonactions, consents
and approvals from Governmental Authorities necessary in connection with the
consummation of the transactions contemplated under this Agreement and the other
Transaction Documents and the making of all necessary registrations and filings
(including but not limited to filings with any Governmental Authorities) and the
taking of all reasonable steps as may be necessary to obtain an approval from,
or to avoid an action or proceeding by, any Governmental Authority necessary in
connection with the consummation of the transactions contemplated under this
Agreement and the other Transaction Documents shall be made by the Company prior
to Closing. The term “Governmental Authority” shall
mean any foreign or domestic governmental body, self-regulatory organization,
court, agency, commission, official or regulatory or other authority, including
but not limited to the SEC, the OTC Bulletin Board or any other stock
exchange.
20
(q) Amendment of Conditional
Warrant. Warrant number F08-2 issued by the Company to the Investor on
February 27, 2008 (the “Conditional Warrant”) shall be
amended such that the Conditional Warrant shall be exercisable upon Closing,
subject to the other terms and conditions contained in the amendment to the
Conditional Warrant (the “Amendment to the Conditional
Warrant”), in substantially the form attached hereto as Exhibit D;
(r) Amendment of the June
Notes. Those certain three convertible promissory notes (the
“June Notes”) in the aggregate
principal amount of US$ 10,000,000, granted to the Investor by the Company
pursuant to that certain Note and Warrant Purchase Agreement, dated as of June
1, 2008, shall be amended pursuant to the terms and conditions as set forth in
the Amendment to the Notes (the “Amendment to the Notes”), in
substantially the form attached hereto as Exhibit E;
(s) Amendment of the December
Note. That certain note (the “December Note”) in the
aggregate principal amount of US$ 3,000,000, granted to the Investor by the
Company pursuant to that certain Note Purchase Agreement, dated as of November
17, 2008, shall be amended such that the maturity date of the December Note
shall be extended to March 17, 2010, pursuant to the terms and
conditions as set forth in the amendment to the December Note (the “Amendment to the December
Note”), in substantially the form attached hereto as Exhibit F;
(t) Transaction Documents. The
Company shall have executed all agreements and documents and satisfied all
conditions as required to be executed or satisfied at the Closing pursuant to
the Transaction Documents;
(u) Filing of Schedule 14F-1 with the
SEC. At or prior to the Closing, the Company shall file a
Schedule 14F-1 with the SEC and shall distribute such form to the Company’s
stockholders, indicating the intent of the Company to restructure the Board of
Directors in accordance with Section 6(v).
(v) Board of
Directors. At or prior to Closing, four (4) existing directors
shall resign from the Board of Directors of the Company (expected to be Xxxxx
Xxxxx, Xxxxxxx Xxxxx, Xxxxx Xxxxxx and Xxx Xxxxxxx). Immediately
following the Closing, the remaining members of the Board of Directors (expected
to be Xx. Xxxxxx Xxxxxxx, Xxxxx Xxxxx and X.X. “Xxxx” Xxxxxx) shall approve the
election of one (1) replacement to the Board of Directors in
accordance with the instructions of the Investor, expected to be Xx. Xxxxxxxx
Xxxxxxxxxxxxx, whose appointment shall take effect at such time, and a second
replacement to the Board of Directors in accordance with the instructions of the
Investor, expected to be Xx. Xxxxxx xxx Xxxxxxxxx, whose appointment shall take
effect after the expiration of the ten (10) day period following the Company’s
filing of a Schedule 14F-1 with the SEC and distribution of such Schedule 14F-1
to the Company’s stockholders (any directors nominated by the Investor, expected
to consist of Xx. Xxxxxx, Xx. Xxxxxxxxxxxxx and Dr. von Rueckman, hereinafter
referred to as an “Investor
Director”).;
21
(w) Key Man Insurance. The Company shall
acquire life insurance on the life of the Chief Executive Officer of the Company
in an amount of one million Dollars (USD 1,000,000), naming the Company as
beneficiary; and
(x) D&O Insurance. The Company shall
procure a directors’ and officers’ insurance policy, covering the Company’s
board of directors, in an amount of no less than five million Dollars (USD
5,000,000), and shall pay all required premiums with respect to, and maintain in
effect, such directors’ and officers’ insurance policy.
7. Conditions to
Obligations of the Company. The Company’s obligation to issue
and sell the Note at the Closing is subject to the fulfillment, on or prior to
the Closing Date, of the following conditions, any of which may be waived in
whole or in part by the Company:
(a) Representations and
Warranties. The representations and warranties made by the Investor in
Section 4 shall be true and correct when made, and shall be true and
correct on the Closing Date;
(b) Performance. The
Investor shall have performed, satisfied and complied in all material respects
with all covenants, agreements and conditions required by the Transaction
Documents to be performed, satisfied or complied with by such Investor at or
prior to the Closing Date;
(c) No Injunction. No
statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by any court or Governmental
Authority of competent jurisdiction that prohibits the consummation of any of
the transactions contemplated by the Transaction Documents;
(d) Transaction Documents. At the
Closing, the Investor shall have duly executed and delivered to the Company this
Agreement, the Security Agreement, the Amended and Restated Registration Rights
Agreement, the Amendment to the Notes, the amendment to the December Note and
the Amendment to the Conditional Warrant; and
(e) Purchase
Price. The Investor shall have delivered to the Company the
Purchase Price in accordance with Section 2.
8. Events of
Default. If any of the
following events (each, an “Event of Default”) shall
occur:
(a) Voluntary Bankruptcy or Insolvency
Proceedings. The Company shall
(i) apply for or consent to the appointment of a receiver, trustee,
liquidator or custodian of itself or of all or a substantial part of its
property, (ii) be unable, or admit in writing its inability, to pay its
debts generally as they mature, (iii) make a general assignment for the
benefit of its or any of its creditors, (iv) be dissolved or liquidated,
(v) commence a voluntary case or other proceeding seeking liquidation,
reorganization or other relief with respect to itself or its debts under any
bankruptcy, insolvency or other similar law now or hereafter in effect or
consent to any such relief or to the appointment of or taking possession of its
property by any official in an involuntary case or other proceeding commenced
against it, or (vi) take any action for the purpose of effecting any of the
foregoing; or
22
(b) Involuntary Bankruptcy or Insolvency
Proceedings. Proceedings for the appointment of a receiver, trustee,
liquidator or custodian of the Company or of all or a substantial part of the
property thereof, or an involuntary case or other proceedings seeking
liquidation, reorganization or other relief with respect to the Company or the
debts thereof under any bankruptcy, insolvency or other similar law now or
hereafter in effect shall be commenced and an order for relief entered or such
proceeding shall not be dismissed or discharged within 60 days of commencement;
or
(c) Material Breach. The Company
shall breach any term of this Agreement, any of the Transaction Documents or any
other agreement or instrument executed in connection therewith, which,
individually or in the aggregate, materially and adversely affects any of the
Investor’s rights under this Agreement or any of the Transaction Documents, and
as to any breach that is capable of cure, the Company fails to cure such breach
within fifteen (15) days after the Investor provides written notice to the
Company of such breach; or
(d) Exit Event. Upon the
occurrence of any of the following events: (i) a merger or consolidation or
other change of control involving the Company, other than a merger or
consolidation involving the Company or a subsidiary in which the capital stock
of the Company outstanding immediately prior to such transaction continues to
represent, or is converted into or exchanged for, capital stock that represents,
immediately following such transaction, at least a majority by voting power of
the capital stock of (A) the surviving or resulting company or (B) if the
surviving or resulting company is a wholly-owned subsidiary of another company
immediately following such merger or consolidation, the parent company of such
surviving or resulting company; (ii) a sale of a majority of the then
outstanding Common Stock in the Company on an as converted basis; or (iii) a
sale, lease, exclusive license or other disposition of all or substantially all
of the assets of the Company; or
(e) Exclusivity Violation. There
is an Exclusivity Violation (as defined in the term sheet signed by the parties
to this Agreement on February 7, 2009) and the Company fails to pay to the
Investor the principal balance of the Note plus accrued and unpaid interest
within five (5) Business Days following the date of the Exclusivity
Violation.
Then,
upon the written consent of the Investor and in any such event and at any time
thereafter if such Event of Default or any other Event of Default shall have not
been waived by the Investor, the Investor may declare by notice to the Company
this Note and all other outstanding notes issued to the Investor (including the
December Notes and the June Notes, if still outstanding, and together with the
Note, the “Notes”) due
and payable, upon which an amount equal to the aggregate principal amount of the
Notes and any accrued interest and any other amounts owing under the Notes,
immediately shall be due and payable, and the same shall forthwith become
immediately due and payable without presentment, demand, protest, notice or
other formality of any kind, all of which are hereby expressly
waived.
23
9. Miscellaneous.
(a) Waivers and Amendments. Any
provision of this Agreement may be amended, waived or modified only upon the
written consent of the Company and the Investor.
(b) Governing Law. This Agreement
and all actions arising out of or in connection with this Agreement shall be
governed by and construed in accordance with the laws of the State of
California, without regard to the conflicts of law provisions of the State of
California or of any other state.
(c) Survival. The
representations, warranties, covenants and agreements made herein shall survive
the execution and delivery of this Agreement.
(d) Successors and Assigns.
Subject to the restrictions on transfer described in Sections 9(e)
and 9(f) below, the rights and obligations of the Company and the
Investor shall be binding upon and benefit the successors, assigns, heirs,
administrators and transferees of the parties.
(e) Registration, Transfer and
Replacement of the Note. The Note issuable under this Agreement shall be
registered in the records of the Company. The Company will keep, at
its principal executive office, books for the registration and registration of
transfer of the Note. Prior to presentation of the Note for
registration of transfer, the Company shall treat the Person in whose name the
Note is registered as the owner and holder of the Note for all purposes
whatsoever, whether or not the Note shall be overdue, and the Company shall not
be affected by notice to the contrary. Subject to the restrictions on
or conditions to transfer set forth in this Agreement or in the Note, the holder
of the Note, at its option, may in person or by duly authorized attorney
surrender the same for exchange at the Company’s principal executive office, and
promptly thereafter and at the Company’s expense, except as provided below,
receive in exchange therefor one or more new Note(s), each in the principal
requested by such holder, dated the date of the Note so surrendered and
registered in the name of such Person or Persons as shall have been designated
in writing by such holder or its attorney for the same principal amount, in the
aggregate, as the principal amount of the Note so
surrendered. Upon receipt by the Company of evidence reasonably
satisfactory to it of the ownership of and the loss, theft, destruction or
mutilation of any Note and (a) in the case of loss, theft or destruction,
of indemnity reasonably satisfactory to it; or (b) in the case of
mutilation, upon surrender thereof, the Company, at its expense, will execute
and deliver in lieu thereof a new Note executed in the same manner as the Note
being replaced, in the same principal amount as the principal amount of the Note
and dated the date of the Note.
(f) Assignment by the Company.
The rights, interests or obligations hereunder may not be assigned, by operation
of law or otherwise, in whole or in part, by the Company.
(g) Entire Agreement. This
Agreement together with the other Transaction Documents constitute and contain
the entire agreement among the Company and the Investor and supersede any and
all prior agreements, negotiations, correspondence, understandings and
communications among the parties, whether written or oral, respecting the
subject matter hereof.
24
(h) Notices. All notices and
other communications made pursuant to this Agreement shall be in writing and
shall be conclusively deemed to have been duly given:
(i) in
the case of hand delivery to the address set forth below, on the next Business
Day after delivery;
(ii) in
the case of delivery by an internationally recognized overnight courier to the
address set forth below, freight prepaid, on the next Business Day after
delivery and signed receipt by the recipient; and
(iii) in
the case of a notice sent by facsimile transmission to the number and addressed
as set forth below, on the next Business Day after delivery, if receipt of such
facsimile transmission is confirmed.
For all
notices given pursuant to one of the methods listed above, a copy of the notice
should also be sent by email to the email address set forth below.
Contact
details:
If to
Investor:
Address for notices being delivered
by hand/courier:
c/o
Inventages Whealth Management Inc.
Winterbotham
Place, Marlborough & Queen Streets
P. O. Box
N-3026
Nassau,
The Bahamas, Attn: Xx. Xxxxxx Xxxxxxx
Always
with a copy to: IVC SA, Xxxxx xx Xxxxxx 00X, 0000 -
Xxxxxxxx,Xxxxxxxxxxx, Attn: Xx. Xxxxxx xxx Xxxxxxxxx
Always
with a copy to: xxxxxxx@xxxxxxxxxx.xxx
and xxxxxxxxx@xxxxxxxxxx.xxx
Number for notices being delivered by
facsimile transmission:
To: IVC SA,
Attn: Xx. Xxxxxx xxx Xxxxxxxxx, at: x00 00 000
0000
Always
with a copy to: xxxxxxx@xxxxxxxxxx.xxx
and xxxxxxxxx@xxxxxxxxxx.xxx
25
If to the
Company:
Address for notices being delivered
by hand/courier:
Organic
To Go Food Corporation
0000
Xxxxx Xxxxxx Xxxxx
Xxxxxxx,
Xxxxxxxxxx 00000
Attn:
Chief Financial Officer
Always
with a copy to:
Loeb
& Loeb LLP
00000
Xxxxx Xxxxxx Xxxxxxxxx
Xxxxx
0000
Xxx
Xxxxxxx, Xxxxxxxxxx 00000
Attention:
Xxxxxxxx Xxxxxx, Esq.
Number
for notices being delivered by facsimile transmission:
To:
Organic To Go Food Corporation, Attn: Chief Financial Officer, at: x0000 000
0000
Always with a copy to: Loeb & Loeb
LLP, Attn: Xxxxxxxx Xxxxxx, Esq, at:x0 000 000 0000
A party
may change or supplement the contact details for service of any notice pursuant
to this Agreement, or designate additional addresses, facsimile numbers and
email addresses for the purposes of this Section 9(h) by giving the other
parties written notice of the new contact details in the manner set forth
above.
(i) Arbitration. Each party
agrees that any dispute, controversy, or claim arising in relation to this
Agreement, including with regard to its validity, invalidity, breach,
enforcement or termination, shall be resolved by binding arbitration in London,
England, in accordance with the rules of arbitration which are in force in the
United Kingdom on the date when the notice of arbitration is
submitted. The arbitrability of such dispute, claim or controversy
shall also be determined in such arbitration. Such arbitration proceeding shall
be conducted in the English language before one (1) arbitrator agreed to by the
parties. Both the foregoing agreement of the parties to arbitrate any and all
such disputes, claims and controversies, and the results, determinations,
findings, judgments and/or awards rendered through any such arbitration shall be
final and binding on the parties hereto and may be specifically enforced by
legal proceedings.
26
(j) Fees
and Expenses
(i) The
Company agrees to be billed directly and to pay upon Closing (i) all reasonable
costs and expenses, including out-of-pocket travel expenses, incurred by any and
all counsel, attorneys, consultants, auditors, experts and representatives of
the Investor, in connection with the performance of the due diligence related to
this Agreement and the negotiation, preparation, execution, delivery and
implementation of this Agreement, not to exceed one hundred and seventy five
thousand Dollars (USD 175,000) (the “Investment Expenses”); and
(ii) following a failure to reach the Closing due to Company’s failure to comply
with the conditions to Closing, (x) the Investment Expenses, plus (y) all costs
and expenses, including reasonable legal fees, incurred by the Investor in
collecting payment for the Investment Expenses and in otherwise enforcing
compliance with the terms of this Agreement (the “Compliance Expenses”), plus
(z) the sum of two hundred fifty thousand Dollars (USD 250,000) as liquidated
damages (and not as penalty) (the “Liquidated
Damages”).
(ii) The
Company will be liable for all Investment Expenses, Compliance Expenses and
Liquidated Damages if the parties fail to achieve the Closing due to the
Company’s failure to comply with the conditions to the Closing set forth in this
Agreement, subject to a written notice of such failure by the Investor to the
Company. Notwithstanding the aforesaid compensation, upon the
non-compliance of the Company with the Closing conditions of this Agreement, the
Investor shall be entitled to any and all remedies available to it under
applicable law.
(k) Severability. If
any provision of this Agreement is held to be invalid or unenforceable in any
respect, the validity and enforceability of the remaining terms and provisions
of this Agreement shall not in any way be affected or impaired thereby and the
parties will attempt to agree upon a valid and enforceable provision that is a
reasonable substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.
(l) Limitation of Liability.
Notwithstanding anything herein to the contrary, the Company acknowledges
and agrees that no trustee, officer, investment vehicle, investor, shareholder
or holder of shares of beneficial interest of the Investor shall be personally
liable for any liabilities of the Investor.
(m) Counterparts. This Agreement
may be executed in one or more counterparts, each of which will be deemed an
original, but all of which together will constitute one and the same
agreement. Facsimile copies of signed signature pages will be deemed
binding originals.
[Signature
Page Follows]
27
The
parties have caused this Agreement to be duly executed and delivered by their
proper and duly authorized officers as of the date and year first written
above.
COMPANY:
ORGANIC
TO GO FOOD CORPORATION
a
Delaware corporation
|
|||
By:
|
|||
Name:
Xxxxx Xxxxx
Title:
Chairman and Chief Executive Officer
|
|||
INVESTOR:
X.XXXXXX
L.P.
|
|||
By:
|
|||
Xx.
Xxxxxx Xxxxxxx
Director,
Inventages Whealth Management, Inc., as General Partner of X.Xxxxxx
L.P.
|
|||
By:
|
|||
Xx.
Xxxxxxxx Xxxxxxxxxxxxx
Director,
Inventages Whealth Management, Inc., as General Partner of X.Xxxxxx
L.P.
|
|||
DISCLOSURE
SCHEDULE
Exhibit
A
Note
Exhibit
B
Security
Agreement
Exhibit
C
Investor
Questionnaire
Organic
To Go Food Corporation (the “Company”) will use
the responses to this questionnaire to qualify prospective investors for
purposes of U.S. securities laws.
Your
answers will be kept confidential at all times. However, by signing
this questionnaire, you agree that the Company may present this questionnaire to
such parties as it deems appropriate to establish the availability of exemptions
from registration under U.S. securities laws.
Investor:
|
|
Exact
name as it should appear on the Note. If the name is a “nominee
name,” please so state and in addition, provide the name of the legal
owner.
|
|
Address
|
|
Address
for securityholder records. All notices and mailings will be
made to this address. Indicate, if appropriate, the person at
that address to whose attention the mailing should be
directed.
|
1. Representations, Warranties
and Agreements. In order for the Company to offer the Note
(the “Note”) in
conformance with Regulation S (“Regulation S”)
promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the
following information must be obtained. (For purposes of answering
the following questions, the term “United States” means the United States of
America, its territories and possessions, any State of the United States and the
District of Columbia.)
(a) Please
initial the blank that correctly responds to the following statement: The
undersigned is not purchasing the Note for the account or benefit of any person,
entity, group or organization that resides in the United States or has a place
of business in the United States.
True | ||
False
|
(b) Please
initial the blank that correctly responds to the following statement: (i) the
undersigned did not receive an offer to subscribe for the Note in the United
States (as defined above); and (ii) this
Investor Suitability Questionnaire (“Questionnaire”) is
being executed and entered into outside of the United States (as defined
above).
True | ||
False
|
(c) The
undersigned agrees to transfer the Note only in accordance with the provisions
of Regulation S, pursuant to registration under the Securities Act or pursuant
to an available exemption from registration under the Securities
Act. Any transfer in violation of the preceding sentence will be null
and void and the Company will not recognize any such attempted
transfer. The undersigned acknowledges that the Note is characterized
as a “restricted security” under U.S. federal securities laws and may be resold
without registration under the Securities Act only in certain limited
circumstances. Additionally, the Note may be subject to certain
contractual limitations on transferability.
True | ||
False
|
Indicate
the form of entity of the undersigned:
Individual
|
||
Corporation
|
||
Limited
Partnership
|
||
General
Partnership
|
||
Limited
Liability Company
|
||
Trust
|
||
Other
form of organization (indicate form of organization):
|
||
The
foregoing representations and warranties are true and accurate as of the date
hereof and shall be true and accurate as of the date of the closing (the “Closing”) of any sale
of the Note to the undersigned and shall survive such date. If in any respect such
representations and warranties shall not be true and accurate prior to Closing,
the undersigned shall give immediate notice of such fact to the Company,
specifying which representations and warranties are not true and accurate and
the reasons therefor.
2. Indemnification. The
undersigned understands the meaning and legal consequences of the
representations and warranties made by the undersigned herein, and that the
Company is relying on such representations and warranties in making its
determination to accept or reject the undersigned’s offer to purchase the Note
in this offering. The undersigned hereby agrees to indemnify and hold
harmless the Company and each director, officer, employee or agent thereof from
and against any and all loss, damage or liability due to or arising out of a
breach of any representation or warranty of the undersigned contained in this
Questionnaire.
3. Survival of Representations,
Warranties and Agreements. All representations, warranties and
agreements contained herein or made in writing by or on behalf of the
undersigned in connection with the transactions contemplated hereby shall
survive the Closing of any sale of the Note by the Company to the
undersigned.
4. Headings. The
headings in this Questionnaire are for convenience of reference, and shall not
by themselves determine the meaning of this Questionnaire or of any part
hereof.
CORPORATIONS,
PARTNERSHIPS, LLCs, TRUSTS AND OTHER ENTITIES
Date:
November __, 2008
NAME
OF ENTITY
|
|
BY
(Signature)
|
|
PRINT
NAME
|
|
TITLE
|
|
PRINCIPAL
PLACE OF BUSINESS:
|
|
NUMBER
AND STREET
|
|
CITY/PROVINCE/COUNTRY/POSTAL
CODE
|
|
TELEPHONE
NUMBER
|
|
FAX
NUMBER
|
Exhibit
D
Amendment
to the Conditional Warrant
Exhibit
E
Amendment
to the Notes
Exhibit
F
Amendment
to the December Note
Exhibit
G
Amended
and Restated Registration Rights Agreement